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Abstract
Background: Women with a history of a hypertensive disorder during pregnancy (HDP) have an increased risk of
cardiovascular events. Guidelines recommend assessment of cardiovascular risk factors in these women later in life, but
provide limited advice on how this follow-up should be organized.
Design: Systematic review and meta-regression analysis.
Methods: The aim of our study was to provide an overview of existing knowledge on the changes over time in three
major modifiable components of cardiovascular risk assessment after HDP: blood pressure, glucose homeostasis and
lipid levels. Data from 44 studies and up to 6904 women with a history of a HDP were compared with risk factor levels
reported for women of corresponding age in the National Health And Nutrition Examination Survey, Estudio
Epidemio´logico de la Insuficiencia Renal en Espan˜a and Hong Kong cohorts (N¼ 27,803).
Results: Compared with the reference cohort, women with a HDP presented with higher mean blood pressure.
Hypertension was present in a higher rate among women with a previous HDP from 15 years postpartum onwards.
At 15 years postpartum (age 45), one in five women with a history of a HDP suffer from hypertension. No differences
in glucose homeostasis parameters or lipid levels were observed.
Conclusions: Based on our analysis, it is not possible to point out a time point to commence screening for cardio-
vascular risk factors in women after a HDP. We recommend redirection of future research towards the development of a
stepwise approach identifying the women with the highest cardiovascular risk.
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Introduction
Large cohort studies have consistently demonstrated an
increased risk – up to seven-fold – of cardiovascular
disease (CVD) later in life in women with a history of
hypertensive disorders of pregnancy (HDPs) compared
with women with uncomplicated pregnancies.1,2
Manifestation of CVD occurs earlier in HDPs: approxi-
mately 6–8 years before controls.1,2 Consensus on
which mechanisms contribute to this increased risk
has not been established. Current opinion is that
HDP and CVD share common risk factors, including
sympathetic driven hypertension, insulin resistance,
inﬂammation and obesity.1,3 Also pregnancy itself has
been proven to enlarge future CVD risk: parity was
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independently associated in a J-shaped fashion, with
two births representing the lowest risk.4,5
Pregnancy induces an extensive adaptation of the
circulatory system, including major cardiac output
and renal glomerular changes. Pregnancy may
unmask limited cardiovascular reserves resulting in
HDP and thus pregnancy complicated by HDP can
be considered as a failed cardiovascular stress test.6
Therefore, positive history of HDP may allow for
early identiﬁcation of women at risk of CVD and pro-
vide opportunities for prevention and intervention.7
The last three decades, there is an increasing impera-
tive for primary CVD prevention in women.8
Unfortunately, guidelines still fail to provide a uniform
recommendation on risk stratiﬁcation based on sex spe-
ciﬁc risk factors, such as HDP and subtypes.4 The
American Colleges of Obstetrics and Gynaecologists’
Task Force on Hypertension in Pregnancy emphasizes
the opportunity that early identiﬁcation of a group of
young women at risk oﬀers for prevention, but
appoints solely women with preterm pre-eclampsia or
recurrent pre-eclampsia to be eligible for screening,
whereas other guidelines do not discriminate between
HDP phenotypes.9–12 All guidelines suggest evaluation
of blood pressure after HDP, although their recommen-
dation regarding the commencement and the time inter-
val of screening diﬀers.9–13 The recently published
Dutch multidisciplinary guideline suggests optimization
of modiﬁable cardiovascular risk factors to reduce risk
of future CVD. The recommendation to screen at age
50 was obtained by consensus between the diﬀerent
participating disciplines rather than based on evidence.
Identiﬁcation of deviating risk factor patterns is
required to ﬁnd a window of opportunity for screening
and possibly allows for the creation of preventative pro-
grammes to reverse the increased risk of CVD.
Established risk factors for CVD as adopted by the
American Heart Association and the European Society
of Cardiology risk assessment tools are age, sex, blood
pressure, diabetes, lipid level, smoking, family history,
impaired renal function, physical inactivity and body
weight.11,14 Existing evidence on the development of
these risk factors in HDPs lacks longer follow-up.
Only few studies reported on the fourth and ﬁfth
decade of life, the time frame in which the ﬁrst clinical
signs of cardiovascular disease is expected.7
We aim to provide an insight into the risk proﬁle
development of women who experienced HDP by
performing a systematic review and meta-regression
analysis on the course of blood pressure, fasting glucose
and homeostasis model assessment of insulin resistance
(HOMA-IR) as parameters for glucose metabolism and
high-density lipoprotein cholesterol (HDL-C) and
low-density lipoprotein cholesterol (LDL-C) in HDPs
compared with a reference cohort.
Methods
Data sources and searches
A systematic literature search in PubMed, Embase and
The Cochrane Library was conducted. No ﬁlters were
used, nor restrictions on publication year. Relevant
synonyms for [history of hypertensive disorders of preg-
nancy] and [risk factor#] (#blood pressure OR glucose
OR insulin OR HOMA-IR OR HDL-C OR LDL-C)
were combined. After title and abstract screening by
TKJG, remaining articles were screened on full text.
Screening was performed based on the article’s content
meeting our inclusion criteria. The reference lists of
selected articles, related reviews and meta-analyses
were manually searched for additional eligible articles.
Detailed search strategies are described in supplement 1
in the Supplementary Material online.
Eligibility criteria
We included prospective and retrospective cohort stu-
dies assessing women of any parity or age or with a
history of a HDP. A cohort study was deﬁned as a
study that identiﬁed HDP as determinant and reported
on selected risk factors as outcome. The relevance and
validity of the studies was assessed using the
Newcastle–Ottawa Scale15 with some additions accord-
ing to the evidence-based medicine guidelines as stated
by Scholten et al.16 (Supplementary Material supple-
ment 2 – critical appraisal table and legend).
Relevance of the study ﬁndings for applicability
involved evaluation of the study population and
reported outcomes (the prementioned risk factors).
Studies in women with pre-existing cardiovascular co-
morbidities – such as pre-existent hypertension, renal
failure and cardiac disease – prior to the index preg-
nancy were excluded from the analysis. Also studies
conducted in women with previous early pre-eclampsia
were excluded, for the pathophysiological mechanisms
including vascular remodelling and risk factors asso-
ciated with this type of HDP are thought to be diﬀerent
and thus the course to later CVD might be too.17,18
Classiﬁcation of the validity of the studies consisted
of the evaluation of: selective inclusion, standardization
of HDP and outcome and completeness of data,
respectively loss to follow-up and missing data.
Minimally, HDP status assessment was conducted
through clinical and laboratory diagnostics.
Assessment of HDP status based on recall through a
questionnaire was considered of insuﬃcient reliability.
We also excluded articles that reported on only preva-
lence of the risk factor (e.g. hypertension, diabetes)
rather that mean values for the derivative measurement
(blood pressure, fasting glucose). Due to diﬀerences in
the deﬁnition of the risk factors, these were considered
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too heterogenic to incorporate into a reliable meta-ana-
lysis. Each relevance and validity criterion was classi-
ﬁed with a two or three point scoring system. Only
articles of suﬃcient methodological quality were
included in the meta-analysis.
Statistical analysis
Studies were divided into groups based on years of
follow-up from index pregnancy. Per category weighted
mean values (w¼Pði  piÞ) and standard deviations
(variance s2 ¼P piði wÞ2; standard deviation
s¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃvariancep ) were calculated. Given weighted
means and standard deviations, number of participants
with values above treatment thresholds could be calcu-
lated using Excel normal distribution formulas.19
Per risk factor, weighted mean values of women with
a history of HDP were compared with reference
cohorts. Blood pressure data were compared with the
data of the Third National Health And Nutrition
Examination Survey (NHANES III; 1988–1994),
which consisted of 15.326 female US natives of 18–74
years old.20 Oﬃcially, the deﬁnition of hypertension
contains both a systolic (140mmHg) and diastolic
(90mmHg) threshold. However, since we rely on
reported cohort means, we were unable to extract indi-
vidual data to see if patients would meet either of these
criteria. As cardiovascular risk scores such as SCORE
and SMART have their risk estimation based on sys-
tolic pressure we decided to deﬁne hypertension based
on the systolic blood pressure only.11,21
The weighted mean fasting glucose values of all cases
calculated as described above are compared with 11,148
women, citizens of Hong Kong.22 Age category speciﬁc
weighted mean fasting insulin and glucose were used to
calculate homeostasis model assessment of insulin
resistance (HOMA-IR), if not already reported by the
selected articles. The ATP III (Third Adult Treatment
Panel) age speciﬁc HOMA-IR values for non-diabetic
women were used as reference, as these were reported
most sensitive and speciﬁc in the EPIRCE study
(N¼ 1329).23 The data from the 1994–2002 NHANES
cohort were used as control cohort for HDL-C and
LDL-C levels data based on 4549 female adults of 20
years and older.24
Results
Study selection
The systematic search (supplement 1, Supplementary
Material) yielded 8709 unique studies. Figure 1 shows
the articles retrieved from the searches, reviewed and
included in the analysis. After selection based on title
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Figure 1. Flowchart (last search 20 October 2015).
HDP: hypertensive disorder during pregnancy
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and abstract and subsequent full-text screening, 91 art-
icles were considered potentially eligible for answering
our question. Thirteen articles were excluded based on
determinant discrepancies25–37 (supplement 2 – critical
appraisal Table 1). Four studies were at risk for selec-
tion bias.38–41 The eligible outcomes were missing or
reported with incompatible stratiﬁcation in seven stu-
dies.42–49 Three studies used a questionnaire to establish
previous HDP, which was thought to be of insuﬃcient
reliability.37,50,51 Fifteen articles were excluded from
analysis for they reported only prevalences of hyperten-
sion, diabetes or dyslipidaemia and not mean
values.52–67 Last, two studies reported too large propor-
tion of loss to follow-up.68,69 When two manuscripts
were published on the same cohort, the oldest was
excluded.70–72
Study characteristics
Table 2a in supplement 3 lists the characteristics of the
36 studies reporting on blood pressure. The majority of
the studies report on women with a history of pre-
eclampsia.35,72–96 Sample sizes diﬀer from 2679 to
322588 participants. In total the analysis was performed
with 36 studies, consisting of 6904 HDPs.35,65,72–95,97–107
Only two studies reported on women over the age of 55
years.80,96 All studies report on non-recurrent complica-
tions of pregnancy. If reported, phenotype of HDP is
speciﬁed: pre-eclampsia, pregnancy induced hyperten-
sion (PIH) or both (HDP).
Baseline characteristics of the studies on fasting glu-
cose, fasting insulin, HOMA-IR, HDL-C and LDL-C
are displayed in Tables 2b and 2c (supplement 3).
Blood pressure
HDPs had an overall higher mean blood pressure
(Figure 2(a)) compared with controls.35,65,72–95,97–107
The large standard deviation in follow-up categories
15–20 years and 40–45 years post-partum can be
explained by the small sample sizes, for both categories
consist of only two studies.65
From 15 years after the index pregnancy onwards,
HDPs show hypertension at a higher rate compared
with reference populations. At 15 year follow-up,
which is approximately at age 45, one in ﬁve
(þ/ 20%) of HDPs suﬀer from hypertension versus
17.6% in the NHANES cohort (p< 0.0001; estimated
0 1
60
70
80
90
100
110
120
130
140
150
160
170
(a) (b)
5 10 15 20 25 30 35 40
Follow up after index pregnancy (years)
m
m
H
g
Cases systolic
Cases diastolic
NHANES  systolic
NHANES diastolic
n =  1023 1906   1226   1297   642    1026    397                          25
0 1
0
10
20
30
40
50
60
5 10 15 20 25 30 35 40
Follow up after index pregnancy (years)
Pe
rc
e
n
ta
ge
(%
)
Case NHANES
n =      1023    1906   1226   1297  642  1026   397                       25
N = 15,326 (entire cohor t)N = 15,326 (entire cohor t)
Figure 2. (a) Weighted mean blood pressure. (b) Prevalence of hypertension. Sample sizes are shown below the x-axis. Ranges or
standard deviations are missing in the plots, since these are not reported in the NHANES manuscript.
NHANES: National Health And Nutrition Examination Survey
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with the standard deviation of our analysis applied to
NHANES for NHANES did not report on standard
deviations). This is illustrated in Figure 2(b), which dis-
plays the calculated percentages of hypertension, derived
from the raw data on mean values and deviations per
follow-up category. The NHANES III cohort is used as
reference, displaying values from the age corresponding
to the mean age per follow-up category.20
Glucose metabolism and lipids
A total of 22 studies in 3032 post-HDP women report-
ing on glucose homeostasis metabolites were included
in the analysis. Sixteen studies reported on post-
pre-eclampsia women, four on multiple phenotypes of
HDP and two combined all phenotypes into the cat-
egory HDP. Sample sizes varied from 13108 to 698109
women with previous HDP. Only Haukkamaa et al.80
and Colle´n et al.96 reported on fasting glucose and insu-
lin after the age of 50.
Figure 3(a) and (b) displays mean fasting glucose
and HOMA-IR over follow-up time after index preg-
nancy.35,73,80,81,83,84,89,94–96,98,99,102,103,107–115 In the ana-
lysis of the course of fasting glucose development over
time, no diﬀerence between HDPs and controls can be
detected. The control cohort for the fasting glucose is
formed by 11,148 Chinese women from the Hong Kong
cohort of Ko et al.22 The age speciﬁc thresholds accord-
ing to ATP III as calculated in the EPIRCE trial were
used to compare with HOMA-IR data in the HDPs.116
In all 24 studies combined, 5304 former HDP
women contributed to the analysis on lipid
spectrum. Weighted mean values for HDL-C and
LDL-C are displayed in Figure 3(c) and
(d).35,71,72,74,80,81,84,89,91,95,99–103,106–111,113,114,117–119 The
large standard deviation for mean HDL-C in the
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Figure 3. (a) Weighted mean fasting glucose. (b) Homeostasis model assessment of insulin resistance. (c) Weighted mean high-
density lipoprotein cholesterol. (d) Weighted mean low-density lipoprotein cholesterol. Sample sizes are shown below the x-axis.
NHANES: National Health And Nutrition Examination Survey; ATP III: Third Adult Treatment Panel
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10-year post-partum group is because this category
yields only one study.89
Discussion
This meta-regression analysis shows that HDPs have an
overall higher blood pressure during post-partum
follow-up. Furthermore, HDPs develop hypertension
at a faster pace compared with the reference cohort,
reporting on 20% hypertension in HDPs at 15 years
post-partum (approximately age 45).20 In current prac-
tice, women with a history of HDP are discharged from
the obstetrics department without a strategy for cardio-
vascular follow-up although the increased risk of future
CVD is evident.120 Current guidelines are not uniform
in their advice on screening and treatment in women
with a history of HDP.9-13 These data do not show a
speciﬁc time-frame for screening. A stepwise approach
in screening starting at a young age seems to be the
most appropriate strategy. Possibly also other risk fac-
tors then the classical cardiovascular factors could be of
value in this high risk female population.
First we show an overall higher blood pressure with-
out increase in diﬀerence over time after HDP. Second,
our analysis on blood pressure and subsequently calcu-
lated hypertension rates shows hypertension prevalence
from 5% up to 59% at 40 year follow-up after index
pregnancy. Interestingly, when looking at hypertension
rates until 10 years post-partum the NHANES cohort
shows higher rates.20 This could be due to a variable
number of factors: medication use, pooling of data,
non-pregnant subjects (including infertile women).
Growing evidence suggests that female infertility is
associated with increased cardiovascular risk.121
As explained, we excluded studies that reported on
hypertension only, because of diﬀerences in deﬁnition.
These excluded studies report hypertension rates of
10–65%.35,65,72,73,77–81,84,88,89,93,96,98,99,112,114,122,123 The
diﬀerence between reported prevalence of hyperten-
sion is striking; it could imply that our result under-
estimates the number of women with hypertension
after a HDP. Also, prevalence in the excluded studies
might have been subject to publication bias. The
results presented on glucose homeostasis parameters
did not show any diﬀerence in course of development
when comparing post-HDP women with the general
population. Feig et al. did ﬁnd a two-fold increased
risk of developing diabetes when followed up to 16.5
years after pregnancy complicated by HDP.56 Our
analysis is possibly restricted by sample size in
higher age categories, reporting on measurements in
only 22–26 participants. Furthermore, the discrepancy
might be explained by confounding variables, in par-
ticular, obesity, which in itself is associated with insu-
lin resistance, and is a well-known risk factor of HDP
and hypertension.124 HOMA-IR development shows a
decline in the ﬁrst year post-partum, possibly indicat-
ing a remission period after physiological insulin
resistance during pregnancy.125 The World Health
Organization global report on diabetes shows preva-
lence of diabetes in Asia to be 8.7% versus 7.3% in
Europe.126 Our meta-regression analysis involves 26
studies from Europe, two from Asia, 10 from
the Americas and three from the Western Paciﬁc.
The risk of glucose homeostasis disturbances in the
pooled population of our analysis possibly is more
towards the European average. Comparing this with
the Hong Kong cohort might thus have underesti-
mated the diﬀerence between HDPs and the ‘general’
population.
Regarding lipid levels, small studies conducted pre-
pregnancy and shortly post-partum reported unfavour-
able alterations in lipid spectrum in HDPs compared
with controls.31,81,84,127 However, in larger cohort stu-
dies with longer follow-up, this diﬀerence resolves.64
Finally, in our analysis, with a mean follow-up of
eight years (range 0.1–23 years) the course of HDL-C
and LDL-C over time did not deviate in HDPs com-
pared with reference cohorts. Dyslipidaemia rates
among all female residents are 52% in Europe and
48% in the Americas, resulting in an overestimation
of our analysis. But of the 23 studies on lipids in our
analysis, eight were of Dutch origin, with an average
prevalence 22.4% of dyslipidaemia in the female
population.128
The interpretation of our ﬁndings is hindered by a
few limitations. The studies included in our analysis
mostly report on pre-eclampsia. Hypertension in preg-
nancy is present in approximately 10% of pregnancy;
pre-eclampsia in 2–8% of pregnancy.129 It is thought
that the severity of the event resembles the amount of
cardiovascular distress and consecutive risk of CVD
later in life.130 By pooling all studies, containing diﬀer-
ent phenotypes of HDP assessed at diﬀerent moments
in time, we might have overestimated the real eﬀect of
HDP. Separate analysis of the HDP phenotypes (early
onset pre-eclampsia, late onset pre-eclampsia, preg-
nancy induced hypertension) resulted in insuﬃcient
sample size for meta-analysis. Therefore, we chose to
merge the results into one group of post-HDP women.
Meta-regression does not allow correction for con-
founding (including diﬀerence in body mass index,
age, race, smoking, family history). Methodological
limitations, embedded in the nature of a meta-regres-
sion analysis, including publication bias, have to be
taken into consideration.
The consensus for screening in the HDP population
is inconsistent. The evidence presented in this paper and
other meta-analyses is consistent in terms of blood
pressure, showing increased hypertension risk from
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the age of 45 years onwards. The absolute risk for a car-
diovascular event remains low because these are age
driven and our population of interest is young. It is
understandable that screening strategies are so diverse
since this absolute risk is leading in screening imple-
mentation.131 Second, treatment strategy is not well
investigated. Furthermore, it is unclear who is the high-
est risk (PIH versus pre-eclampsia, early versus late
onset, with and without premature birth and foetal
growth restriction). We question whether future
research should not be redirected towards the develop-
ment of a stepwise screening programme taking all dif-
ferent mechanisms (classical risk factors, HDP
phenotype, genetics, etc.) into account. Combined
with lifestyle behaviour and family history of CVD,
risk stratiﬁcation and consecutive treatment (non-phar-
macological and pharmacological) targets and follow-
up can be established. Since the absolute risk is so low,
the ﬁrst appropriate step would be lifestyle
intervention.132–134
Perspectives
In conclusion, this systematic review and meta-regres-
sion analysis conﬁrmed an altered onset and develop-
ment of hypertension in women with a history of HDP
as compared with women without these pregnancy
complications. We could not identify an optimal time
frame for screening. Interestingly, guidelines published
in the last six years have made diﬀerent recommenda-
tions. We could not perform sub analysis on HDP
phenotype. Phenotyping and other (non-)classical
and/or stepwise CVD risk factor screening and, pos-
sibly, incorporating more mechanistic research could
be the future direction to improve CVD health in this
high risk female population.
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